Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological Parameters in Interleukin-2-treated Systemic Lupus Erythematosus

Trial Profile

Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological Parameters in Interleukin-2-treated Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2018

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms Charact-IL-2
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 31 Aug 2019 to 31 Mar 2020.
    • 01 May 2018 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.
    • 01 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top